Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.

Rheumatology (Oxford) · 2019 · PMC6477523 · PMID 30590813

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Whether treatment with higher doses of secukinumab (300 mg q4Wk) has an even stronger effect on radiographic progression is unknown; a recent study showed a trend towards better clinical effects in some patients [ 19 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.